UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,994	09/22/2006	Satoshi Tanabe	442P105	3238
	42754 7590 03/05/2008 Nields & Lemack		EXAMINER	
176 E. Main Street			KLINKEL, KORTNEY L	
Suite #5 Westboro, MA	01581		ART UNIT	PAPER NUMBER
			4131	
			MAIL DATE	DELIVERY MODE
			03/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/593,994	TANABE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Kortney Klinkel	4131			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>22 Secondary</u> This action is FINAL . 2b)⊠ This Since this application is in condition for alloward closed in accordance with the practice under Expression in the Expression in the practice under Expression in the Expression in th	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-7 is/are pending in the application. 4a) Of the above claim(s) is/are withdrav 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-7 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine	r election requirement.				
10) ☐ The drawing(s) filed on is/are: a) ☐ access Applicant may not request that any objection to the of the conference of the conf	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 11/24/2006.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Art Unit: 1654

DETAILED ACTION

Claims

Claims 1-11 are pending in the instant Office action.

Information Disclosure Statement

Acknowledgement is made of applicant's submitting of the information disclosure statement (IDS) on November 24, 2006. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement (IDS) has been considered by the examiner.

Specification

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Application/Control Number: 10/593,994 Page 3

Art Unit: 1654

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-7 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 of copending Application No. 10/593920. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant application claims a flea control agent characterized by containing an N-substituted indole derivative represented by general formula (I). Co-pending application 10/593920 claims an agent for controlling acarians parasitic on mammals characterized by containing an N-substituted indole derivative represented by general formula (I). Formula (I) is identical in both applications. It is well known in the art that pesticides are often useful for controlling both insects and acarians such as mites and ticks (Witchey-Lakshmanan, Leonore, C. "Long-acting control of ectoparasites: a review of collar technologies for companion animals" *Advanced Drug Delivery Reviews*, 38, 1999, 113-122, see the Introduction (pages 113-115, including Table 1). This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-7 rejected under 35 U.S.C. 102(a) as being anticipated by Tanabe et al. JP200316810 (IDS reference supplied in Japanese with an English abstract; Examiner has included a machine translation of the entire document into English).

Applicants claim a flea control agent containing an N-substituted indole derivative represented by general formula (I).

Application/Control Number: 10/593,994 Page 4

Art Unit: 1654

Tanabe discloses the instant N-substituted indoles of formula (I) as well as their use as a flea controlling agent (claims 1-7, pages 1 and 2 of machine translation). In addition, in claim 6 (page 2 of machine translation) Tanabe discloses a shampoo (instant claim 6) and in claim 7 (page 2), liquid drops (instant claim 7) comprising the flea control agent of instant formula (I). For these reasons, rejection under 35 U.S.C. § 102(a) is proper.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 are rejected under 35 U.S.C. 102 (b) as being anticipated by Hotta ET al. JP6092935 (English abstract provided along with machine translation into English).

Hotta discloses the instant N-substituted indoles of formula (I) and their use in an insecticidal composition (Detailed Description of the Invention, paragraphs 0003-0006 and 0029 for specific types of fleas). For this reason, rejection under 35 U.S.C. § 102(b) is proper.

Conclusion

Claims 1-7 are rejected. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kortney Klinkel, Ph.D. whose telephone number is (571)270-5239. The examiner can normally be reached on Monday-Friday 8am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres (571)272-0867 or Cecilia Tsang (571)272-0562 can be reached at the respective numbers. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Application/Control Number: 10/593,994 Page 5

Art Unit: 1654

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

KLK

/Cecilia Tsang/

Supervisory Patent Examiner, Art Unit 4131